Major Depressive Disorder Clinical Trial
Official title:
Phase I Study of FK949E - Comparison of Pharmacokinetics Between FK949E 50 mg Tablets and FK949E 150 mg Tablets in Patients With Major Depressive Disorder
Verified date | July 2019 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to compare the pharmacokinetics of FK949E low dose tablets and FK949E high dose tablets in non-elderly patients with major depressive disorder. The safety of FK949E in the population was also evaluated.
Status | Completed |
Enrollment | 16 |
Est. completion date | June 22, 2012 |
Est. primary completion date | June 22, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 64 Years |
Eligibility |
Inclusion Criteria: - Patients considered to be able to understand and follow subject requirements, as judged by the investigator/sub-investigator. - Patients diagnosed with major depressive disorder according to the DSM-IV-TR by means of M.I.N.I. - BMI: 17.6 (inclusive) to 26.4 (exclusive). Exclusion Criteria: - Current or past history of DSM-IV-TR Axis I disorder, except major depressive disorder, within the past 6 months before informed consent. - Concurrent DSM-IV-TR Axis II disorder that is considered to greatly affect patient's current mental status. - Current or past history of dependence of substances (other than caffeine and nicotine) or history of abuse or dependence of alcohol. - Unable to suspend treatment with inducers or inhibitors of the drug-metabolizing enzyme, cytochrome P450 3A4 (CYP3A4), for 14 days before the screening assessment and throughout the study. - Patients who could not use an appropriate contraception (condoms) during the study. Patients who were pregnant or lactating. - Patients (carriers) with documented or suspected renal failure, hepatic failure, serious cardiac disease, hepatitis B, hepatitis C, or acquired immunodeficiency syndrome (AIDS). - Patients receiving treatment for hypertension, or patients with concurrent hypertension or unstable angina that may worsen with the study or may affect the study results based on the clinical judgment of the investigator/sub-investigator. - Patients with concurrent hypotension (criterion for hypotension: a systolic blood pressure of less than 100 mmHg), or orthostatic hypotension - Patients with a mean QTcF interval of =450 ms on a 12-lead ECG at the screening assessment - Patients with the risk of torsades de pointe (e.g., those with a history of QT prolongation, those with familial long QT syndrome). - Concurrent malabsorption syndrome, hepatic disease, or other conditions that may affect the absorption and/or metabolism of the study drug. - Concurrent malignancy or history of cured malignancy within 5 years - Current or past history of cerebrovascular disease or transient ischemic attack (TIA). - Received electroconvulsive therapy within 90 days before the screening assessment |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Inc |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum plasma concentration (Cmax) of unchanged quetiapine | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Primary | AUC24h (area under the curve for 24hr) of unchanged quetiapine | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | Trough value of plasma concentration of unchanged quetiapine | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | t1/2 of plasma concentration of unchanged quetiapine | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | Maximum plasma concentration (Cmax) of quetiapine metabolites | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | AUC (area under the curve) of quetiapine metabolites | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | trough value of plasma concentration of quetiapine metabolites | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | tmax of plasma concentration of quetiapine metabolites | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | t1/2 of plasma concentration of quetiapine metabolites | Frequent blood sampling on Day 6 and Day 10 | For 24 hours after dosing | |
Secondary | Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam | Up to Day 11 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |